| Value | ₹56.00 Cr |
|---|
NSE filing, NSE: VALIANTLAB. Summary written from the filing by ALFA Finder's alert engine.
Valiant Laboratories Ltd: key numbers
- Share price
- ₹128.33
- Market cap
- ₹697.0 Cr
- Revenue (annual)
- ₹237.5 Cr
- Net profit (annual)
- ₹-3.27 Cr
- P/E (TTM)
- 43.5×Sector 48.7×
- Promoter holding
- 74.94%+0.00% QoQ
- FII holding
- 0.07%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Valiant Laboratories Ltd
All →Valiant Laboratories Board Meeting Date
Valiant Laboratories will meet on 2 November 2026 to approve half-year audited results. The trading window stays closed until 4 November.
Valiant Laboratories Other Announcement
Valiant Laboratories Ltd has filed its shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI regulations.
Valiant Laboratories Annual General Meeting
Valiant Laboratories Limited successfully conducted its 5th Annual General Meeting on September 28, 2026, transacting 18 agenda items including financial statements and various re-appointments.
Valiant Laboratories Acquisition Worth ₹0.7 Cr
Valiant Laboratories approved acquiring up to 1.01% equity in AMPYR Renewable Energy for ₹0.70 Crore. The investment enables captive solar power for its Tarapur plant.
- Value
- ₹0.70 Cr
- Execution
- 12 months from date of board approval
Valiant Laboratories Other Announcement
Valiant Laboratories Limited has dispatched letters to shareholders who have not registered their email addresses, providing access to the Annual Report and 5th AGM notice.
Valiant Laboratories Annual General Meeting
Valiant Laboratories Limited issued a notice for its Annual General Meeting scheduled for September 28, 2026, covering financial adoption, director appointments, and related party transaction approvals.
Other credit rating announcements
All →Epigral Credit Rating
CRISIL revised Epigral's ratings to CRISIL AA/Stable (long-term) and CRISIL A1+ (short-term) on its bank facilities. The action covers Rs.1,050 Crore of rated bank loan facilities.
Mankind Pharma Credit Rating
CRISIL reaffirmed Mankind Pharma's AA+ rating on Rs.2,500 Crore of NCDs and withdrew ratings on Rs.2,500 Crore NCDs and Rs.1,500 Crore commercial paper. The rating action is dated October 29, 2026.
Lloyds Metals & Energy Credit Rating
Crisil Ratings reaffirmed Lloyds Metals' bank facilities at AA/Stable and A1+, with bank limits enhanced to ₹17,112 crore. It assigned AA/Stable to ₹2,400 crore and ₹1,550 crore of NCDs.
Ram Ratna Wires Credit Rating
CARE Ratings assigned and reaffirmed Ram Ratna Wires' bank facility ratings at CARE A-; Positive / CARE A2+ and revised outlook from Stable to Positive. The long-term bank facilities total Rs.1,046.45 Crore, with several facilities enhanced.
Adani Ports & Special Economic Zone Credit Rating
Fitch Ratings affirmed Adani Ports' Long-Term Foreign-Currency IDR and unsecured notes at 'BBB-' with a Stable outlook. The affirmation keeps the existing rating unchanged.
Capri Global Capital Credit Rating
India Ratings affirmed CGCL's credit rating at IND AA- with Positive outlook. A new Rs. 500 Cr bank loan facility was also assigned the same rating.